ZTS vs. ABBV, PFE, BMY, RPRX, JAZZ, PRGO, CORT, SUPN, PCRX, and NKTR
Should you be buying Zoetis stock or one of its competitors? The main competitors of Zoetis include AbbVie (ABBV), Pfizer (PFE), Bristol-Myers Squibb (BMY), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Corcept Therapeutics (CORT), Supernus Pharmaceuticals (SUPN), Pacira BioSciences (PCRX), and Nektar Therapeutics (NKTR). These companies are all part of the "pharmaceuticals" industry.
AbbVie (NYSE:ABBV) and Zoetis (NYSE:ZTS) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership, valuation and community ranking.
70.2% of AbbVie shares are owned by institutional investors. Comparatively, 92.8% of Zoetis shares are owned by institutional investors. 0.3% of AbbVie shares are owned by company insiders. Comparatively, 0.2% of Zoetis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
AbbVie has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500. Comparatively, Zoetis has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500.
AbbVie has higher revenue and earnings than Zoetis. Zoetis is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.
Zoetis has a net margin of 27.38% compared to Zoetis' net margin of 11.02%. Zoetis' return on equity of 179.47% beat AbbVie's return on equity.
AbbVie received 404 more outperform votes than Zoetis when rated by MarketBeat users. However, 77.82% of users gave Zoetis an outperform vote while only 73.10% of users gave AbbVie an outperform vote.
In the previous week, AbbVie had 21 more articles in the media than Zoetis. MarketBeat recorded 38 mentions for AbbVie and 17 mentions for Zoetis. Zoetis' average media sentiment score of 0.49 beat AbbVie's score of 0.35 indicating that AbbVie is being referred to more favorably in the media.
AbbVie presently has a consensus price target of $176.14, suggesting a potential upside of 9.24%. Zoetis has a consensus price target of $211.75, suggesting a potential upside of 24.88%. Given AbbVie's stronger consensus rating and higher probable upside, analysts plainly believe Zoetis is more favorable than AbbVie.
AbbVie pays an annual dividend of $6.20 per share and has a dividend yield of 3.8%. Zoetis pays an annual dividend of $1.73 per share and has a dividend yield of 1.0%. AbbVie pays out 184.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Zoetis pays out 33.3% of its earnings in the form of a dividend. AbbVie has increased its dividend for 52 consecutive years and Zoetis has increased its dividend for 13 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.
Summary
AbbVie beats Zoetis on 11 of the 21 factors compared between the two stocks.
Get Zoetis News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZTS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ZTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
